DE69301360D1 - Neuroprotektivum - Google Patents

Neuroprotektivum

Info

Publication number
DE69301360D1
DE69301360D1 DE69301360T DE69301360T DE69301360D1 DE 69301360 D1 DE69301360 D1 DE 69301360D1 DE 69301360 T DE69301360 T DE 69301360T DE 69301360 T DE69301360 T DE 69301360T DE 69301360 D1 DE69301360 D1 DE 69301360D1
Authority
DE
Germany
Prior art keywords
cerebral
neuroprotective
neuroprotecting
distrubance
pyrrol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69301360T
Other languages
English (en)
Other versions
DE69301360T2 (de
Inventor
Noriko Yamamoto
Koichi Yokota
Akira Yamashita
Keizo Ito
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kanebo Ltd
Original Assignee
Kanebo Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kanebo Ltd filed Critical Kanebo Ltd
Application granted granted Critical
Publication of DE69301360D1 publication Critical patent/DE69301360D1/de
Publication of DE69301360T2 publication Critical patent/DE69301360T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE69301360T 1992-02-25 1993-02-25 Neuroprotektivum Expired - Fee Related DE69301360T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP4075256A JPH05229943A (ja) 1992-02-25 1992-02-25 脳保護剤

Publications (2)

Publication Number Publication Date
DE69301360D1 true DE69301360D1 (de) 1996-03-07
DE69301360T2 DE69301360T2 (de) 1996-07-11

Family

ID=13570960

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69301360T Expired - Fee Related DE69301360T2 (de) 1992-02-25 1993-02-25 Neuroprotektivum

Country Status (9)

Country Link
US (1) US5399571A (de)
EP (1) EP0560136B1 (de)
JP (1) JPH05229943A (de)
KR (1) KR100247845B1 (de)
AT (1) ATE133335T1 (de)
DE (1) DE69301360T2 (de)
DK (1) DK0560136T3 (de)
ES (1) ES2085665T3 (de)
GR (1) GR3018787T3 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1491194B1 (de) 2002-03-14 2013-10-30 Takeda Pharmaceutical Company Limited Vdac regulator
JP4484439B2 (ja) * 2002-03-14 2010-06-16 国立大学法人東京工業大学 Ｖｄａｃ調節剤
US10471207B2 (en) 2008-12-29 2019-11-12 Medtronic Minimed, Inc. System and/or method for glucose sensor calibration
US9289168B2 (en) * 2008-12-29 2016-03-22 Medtronic Minimed, Inc. System and/or method for glucose sensor calibration

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4168315A (en) * 1977-09-28 1979-09-18 The Upjohn Company Dianisyl thiazole compound, compositions and method of antithrombotic treatment
US4659726A (en) * 1984-04-19 1987-04-21 Kanebo, Ltd. Novel 4,5-Bis (4-methoxyphenyl)-2-(pyrrol-2-yl) thiazoles and pharmaceutical composition containing the same

Also Published As

Publication number Publication date
DK0560136T3 (da) 1996-02-26
KR100247845B1 (ko) 2000-04-01
DE69301360T2 (de) 1996-07-11
ES2085665T3 (es) 1996-06-01
ATE133335T1 (de) 1996-02-15
JPH05229943A (ja) 1993-09-07
US5399571A (en) 1995-03-21
EP0560136A1 (de) 1993-09-15
EP0560136B1 (de) 1996-01-24
GR3018787T3 (en) 1996-04-30
KR930017579A (ko) 1993-09-20

Similar Documents

Publication Publication Date Title
FI935306A7 (fi) Puhdistettujen, pintaa modifioivien aineiden käyttö estämään hiukkasten kasautumista steriloinnin aikana
IL106877A0 (en) Compounds useful as hypoglycemic agents and for treating alzheimer's disease
FI954718A0 (fi) Heterosykliset johdannaiset iskeemian ja vastaavien sairauksien hoitamiseksi
NO990542D0 (no) K-252a-derivater og anvendelse av K-252a-derivater
FI950467L (fi) Terfenadiinin metaboliitit ja niiden optisesti puhtaat isomeerit allergisten sairauksien hoitamiseksi
HRP920667A2 (en) Application of fultripine active substance for preventing muscle deformation
AU3951389A (en) The use of alpha-amino boronicacid derivatives for the prophylaxis and treatment of virus diseases
NO302523B1 (no) Heterosykliske forbindelser, farmasöytiske preparater som omfatter dem, og anvendelse av forbindelsene for fremstilling av medikamenter
NO943521D0 (no) Anvendelse av et pyrrolidinacetamidderivat for fremstilling av et terapeutikum
FI951511L (fi) IL-10:n käyttö insuliinista riippuvan diabetes mellituksen ennaltaestoon tai hoitoon
AU2806692A (en) Medicament for the treatment of anxiety
DK0560136T3 (da) Neurobeskyttende lægemiddel
ITMI931181A1 (it) Procedimento per l'ulteriore trattamento di salcicce
ATE183088T1 (de) Arzneimittel zur behandlung von hauterkrankungen
NO923198D0 (no) Terapeutiske midler
NO960545D0 (no) Behandling av skadelige virkninger i forbindelse med administrering av ekstracellulært hemoglobin
GR3022706T3 (en) Use of 15-dehydroxy-16-oxoprostaglandin derivatives in the treatment of allergic diseases
DE68901172D1 (de) (-)-2-pyrazolinverbindung, deren optischen aufspaltung und therapeutisches agens zur behandlung von zerebralen gefaesskrankheiten, diese verbindung als aktives ingredient enthaltend.
ITMI920161A1 (it) Medicamento contenente arg-gly-asp per il trattamento del glaucoma
FR2691064B3 (fr) Nouveau medicament pour le traitement de l'arythmie.
IL86752A (en) Thiophene derivatives and their preparation and their use as intermediates in the preparation of n-(2,4-dimethylthien-3-yl) -n-(1-methoxyprop-2-yl) - chloroacetamide
KR920700641A (ko) 클로르메티아졸의 신경 변성 예방 및(또는) 치료용 용도
BR9205712A (pt) Medicamento e processo para a preparaçao de um medicamento
SE8703308D0 (sv) Therapeutic agent for the treatment of disorders associated with cerebral ischemia
ES2039255T3 (es) Utilizacion de n-((1-etil-2-pirrolidinil)metil)-2-metoxi-5-sulfamoil-benzamida en el tratamiento de la esterilidad.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee